Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

Recruiting now · Phase 3

Conditions studied: Obesity Control

In brief

This is a 48-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and WEGOVY® in patients with obesity. Eligible participants will be screened and randomized to the experimental group and the active comparator group at a ratio of 1:1 , semaglutide injection or WEGOVY® injection will be given once weekly for 44 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.

Key facts

Study ID
NCT07036172
Run by
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
People needed
460
Starts
2025-01-03
Expected to finish
2026-05-01
Last updated by the study team
2025-06-25

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.